// App-Quantinova.ai

6009 : Genomic Determinants of Response to Pembrolizumab in Head and Neck Squamous Cell Carcinoma.

Researchers

Presenter

  • Robert I. Haddad

Principal Investigators

  • Laura Quan Man Chow

  • Shilpa Gupta

  • Jared Weiss

  • Iris Gluck

  • Joseph Paul Eder

  • Barbara Burtness

  • Makoto Tahara

  • Bhumsuk Keam

  • Hyunseok Kang

  • Kei Muro

  • Andrew Albright

  • Lingkang Huang

  • Mark Ayers

  • Robin Mogg

  • Razvan Cristescu

  • Jonathan D. Cheng

  • Ranee Mehra

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • The University of Chicago Medical Center, Chicago, IL

  • University of Washington, Seattle, WA

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • Unv of North Carolina Lineberger Comp Cancer Ctr, Chapel Hill, NC

  • Yale Cancer Center, New Haven, CT

  • National Cancer Center, EPOC, Chiba, Japan

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Aichi Cancer Center Hospital, Nagoya, Japan

  • Merck & Co., Inc., Kenilworth, NJ

  • Fox Chase Cancer Center, Philadelphia, PA

Locations

  • United States

  • Japan

  • Israel

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • Granulin precursor

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01848834

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved